|
| |

SOLEXA ANNOUNCES THIRD QUARTER 2006
FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 14
HAYWARD, Calif. (November 8, 2006) – Solexa, Inc. (NASDAQ: SLXA) today
announced that it will release financial results for the third quarter of 2006
after market close on Tuesday, November 14, 2006. Solexa management will host an
investment-community conference call at 5:00 p.m. Eastern Time (2:00 p.m.
Pacific Time) to discuss those results and answer questions.
Individuals interested in participating in the conference call may do so by
dialing (800) 366-7417 for domestic callers or (303) 262-2139 for international
callers. Those interested in listening to the conference call live via the
Internet may do so by visiting the Investors section of the Company's Web site
at www.solexa.com .
A webcast replay will be available on the Solexa Web site. A telephone replay
will be available for 48 hours following the conclusion of the call by dialing
(800) 405-2236 for domestic callers, or (303) 590-3000 for international
callers, and entering pass code 11073357#.
- ENDS -
About Solexa
Solexa, Inc. is developing and commercializing the Solexa Genome Analysis
System, which will be used to perform a range of analyses including whole genome
resequencing, gene expression analysis and small RNA analysis. Solexa expects
its first-generation instrument, the 1G Genome Analyzer, to generate over a
billion bases of DNA sequence per run and to enable human genome resequencing
below $100,000 per sample, making it the first platform to reach this important
milestone. Solexa's longer-term goal is to reduce the cost of human
re-sequencing to a few thousand dollars for use in a wide range of applications
from basic research through clinical diagnostics. For further information,
please visit www.solexa.com .
This press release contains "forward-looking" statements, including
statements related to the current views of Solexa management as to future
products, product development, the commercial introduction of the Company's
novel genetic analysis technology and the expansion and success of Solexa's
commercial application of its genomics technologies. Any statements contained in
this press release that are not statements of historical fact may be deemed to
be forward-looking statements. Words such as "believes," "anticipates," "plans,"
"predicts," "expects," "envisions," "hopes," "estimates," "intends," "will,"
"continue," "may," "potential," "should," "confident," "could" and similar
expressions are intended to identify forward-looking statements. There can be no
assurance that such expectations of any of the forward-looking statements will
prove to be correct, and actual results could differ materially from those
projected or assumed in the forward-looking statements. There are a number of
important factors that could cause the results of Solexa to differ materially
from those indicated by these forward-looking statements including, among
others, risks detailed from time to time in the Company's SEC reports, including
its Annual Report on Form 10-K for the year ended December 31, 2005 and its Form
10-Q for the quarter ended June 30, 2006. Solexa does not undertake any
obligation to update forward-looking statements.
For more information, please contact:
European Media Contact:
Northbank Communications
Sue Charles, CEO
s.charles@northbankcommunications.com
Lorna Watson, Account Director
l.watson@northbankcommunications.com
+44 (0)20 3008 7550
Investor Contacts:
EVC Group, Inc.
Doug Sherk
415-896-6818
dsherk@evcgroup.com
Jenifer Kirtland
415-896-2005
jkirtland@evcgroup.com
North American Media Contact:
EVC Group, Inc.
Steve DiMattia
646-277-8706
sdimattia@evcgroup.com
| |
|